-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

EF Hutton Maintains Buy on Century Therapeutics, Lowers Price Target to $16

Benzinga · 01/06/2023 07:29
EF Hutton analyst Tony Butler maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $18 to $16.